Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.50 |
| ▸ | HRH2 | P25021 | 12/20 | 0.50 |
| ▸ | HRH1 | P35367 | 12/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11129382 | 0.92 | MMP2 (0.51) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL7972550 | 0.84 | MMP3 (0.54) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL2356935 | 0.84 | MMP2 (0.50) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL26602050 | 0.83 | MMP3 (0.66) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL9448812 | 0.83 | HDAC1 (0.55) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL14359579 | 0.83 | HDAC1 (0.55) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL18763602 | 0.83 | MMP2 (0.54) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL18079151 | 0.82 | HDAC1 (0.67) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL29444063 | 0.82 | HDAC1 (0.67) | MMP3HRH3HRH2HRH1MMP2 | |
| SCHEMBL16841044 | 0.82 | HDAC1 (0.67) | MMP3HRH3HRH2HRH1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541071-B2 | Liquid-crystalline (METH) acrylate derivatives and composition containing them | CHISSO CORPORATION (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7527746-B2 | Liquid crystal polyfunctional acrylate derivative and polymer thereof | CHISSO CORPORATION (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7527746-B2 | Liquid crystal polyfunctional acrylate derivative and polymer thereof | CHISSO CORPORATION (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060172090-A1 | Liquid crystal polyfunctional acrylate derivative and polymer thereof | JNC PETROCHEMICAL CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172090-A1 | Liquid crystal polyfunctional acrylate derivative and polymer thereof | PYM1, LEO1, AFF1 | MMP3 4206/4885HRH3 2748/4885HRH2 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.